Zhengye Biotechnology Holding (ZYBT) Receivables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has 3 years of Receivables data on file, last reported at $2.7 million in Q4 2025.

• Receivables for Q4 2025 came in at $2.7 million, down 67.71% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.7 million (down 67.71% YoY), and the FY2025 annual result was $2.7 million, down 75.31% from the prior year.
• Receivables retreated to $2.7 million in Q4 2025 per ZYBT's latest filing, from $5.2 million in the prior quarter.
• Over five years, Receivables peaked at $10.5 million in Q4 2023 and troughed at $2.7 million in Q4 2025.
• A 3-year average of $6.7 million and a median of $6.8 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2024 and 2025: Receivables fell 19.91% in 2024, then slumped 67.71% in 2025.
• A 3-year view of Receivables shows it stood at $10.5 million in 2023, then dropped by 19.91% to $8.4 million in 2024, then slumped by 67.71% to $2.7 million in 2025.
• Business Quant data shows ZYBT's Receivables at $2.7 million in Q4 2025, $5.2 million in Q2 2025, and $8.4 million in Q4 2024.